Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (November 2024)
46 slides from Evogene's investor presentation, November 2024
Slide 1: Pioneering New Generation Life-Science Products
PIONEERING NEW GENERATION Life-Science Products OFER HAVIV | PRESIDENT & CEO November 2024
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding o
Slide 3: Agenda
AGENDA About Evogene Success Stories Value Proposition Business Strategy Summary Annex I - Financial overview Annex II - Evogene subsidiaries 3
Slide 4: Our Vision
DECODING BIOLOGY OUR VISION PIONEER GROUNDBREAKING LIFE- SCIENCE PRODUCTS ROOTED IN MICROBES, SMALL MOLECULES, AND GENOMICS 4
Slide 5: Diverse Life-Science Industries
DIVERSE LIFE-SCIENCE INDUSTRIES MICROBES SMALL MOLECULES GENOMICS Microbials Therapeutic Crop Pharmaceuticals Medical for crops microbials protection Alternative Cannabis food Chemical Gene Food OD PHA stimulants OD PHA Advanced OD PHA therapy FO RM FO RM wound care FO RM & A & A Improved & A crops
Slide 6: The Complexity of Life Science Product Development
Pharma Ag-chemicals Industry Industry THE COMPLEXITY Cost of developing a single Years to develop a new crop pharmaceutical drug* protection product** OF LIFE SCIENCE 1995 8Y In the 1970’s PRODUCT $180M 2000 DEVELOPMENT 9Y Low probability of success 2005-2008 with high cost and long In recent years
Slide 7: The Resource Killer
THE RESOURCE KILLER LIFE-SCIENCE PRODUCTS LONG-TAIL PROCESS THE finding the winning candidates out of a vast number of possible prospects that CHALLENGE address a complex myriad of criteria, to reach higher success rate for products > DISCOVERY > OPTIMIZATION > DEVELOPMENT > REGULATION “Needle in th
Slide 8: Historic Singularity Point
TODAY WE ARE ON THE BRINK OF A HISTORIC BIG LIFE- SINGULARITY DATA SCIENCE AI POINT Computational technology advancements enable the LIFE-SCIENCE PRODUCT DEVELOPMENT discovery and optimization of the most promising candidates, addressing multiple development challenges towards successful life-scienc
Slide 9: Our Mission
OUR DECODING BIOLOGY MISSION WE MERGE LIFE-SCIENCE WITH BIG DATA AND CUTTING- EDGE AI TECHNOLOGIES TO EFFECTIVELY DISCOVER AND OPTIMIZE BREAKTHROUGH LIFE-SCIENCE BASED PRODUCTS 9
Slide 10: When Life-Science Meets Disruptive Technologies
WHEN LIFE-SCIENCE MEETS DISRUPTIVE TECHNOLOGIES ISRAEL 2002 EVGN 120 31% 56% HQ Established NASDAQ Employees PhD’s Woman & TASE 3 4 COMMERCIAL Subsidiaries Innovative AI Tech Engines PRODUCTS* Bio-inoculant Castor varieties Microbes Genetic Elements Ag Biologicals Microbiome-based EVF701 Therapeutic
Slide 11: Group Commercial & Financial Partners
COMMERCIAL & Group FINANCIAL PARTNERS Investment & Investment & Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Investment Collaboration 11
Slide 12: Agenda
AGENDA About Evogene Success Stories Value Proposition Business Strategy Summary Annex I - Financial Overview Annex II - Evogene Subsidiaries 12
Slide 13: Lavie Bio Mission
MISSION Evogene’s Improve food quality, sustainability and agricultural productivity Subsidiary through microbiome-based, ag-biological products AG-BIOLOGICALS UNIQUE AI BROAD & STRATEGIC COMMERCIAL A RAPIDLY TECH-PLATFORM DIVERSE INVESTORS & PRODUCT GROWING AND DATA ASSETS PIPELINE PARTNERS MARKET
Slide 14: Yalos Bio-inoculant Yield Improvement
Powered by Evogene’s Yalos® | Bio-inoculant for cereal grains* Subsidiary SOLD IN USA & CANADA** SUPERIOR PERFORMANCE CONSISTENT PERFORMANCE & expanding globally vs. alternatives 6% Check Yield improvement (%) 5% 4% 3% 2% 1% Other Ag-biologicals Control * Yalos® has regulatory approval in the US & C
Slide 15: MicroBoost AI Tech-Engine
MICROBOOST AI TECH-ENGINE Powered by Evogene’s Directing & accelerating product Subsidiary discovery & optimization Computational analysis of DB Powered by Experimental validation ▪ Commercial viability and optimization ~100,000 5% success ▪ Bacterial computational Bacterial teaming by function stra
Slide 16: Yalos Bio-inoculant for Cereal Grains
Powered by Evogene’s Yalos® | Bio-inoculant for cereal grains Subsidiary winter wheat soybean 16
Slide 17: Casterra Mission
MISSION Evogene’s Provide an integrated industrial-scale solution for castor cultivation, utilizing Subsidiary our elite seed varieties, for bio-based industries, with a focus on biofuels. CASTOR OIL - UNIQUE TECH INTEGRATED STRATEGIC COMMERCIAL EMERGING MARKET PLATFORM FOR AG-SOLUTION ALLIANCE PROD
Slide 18: Elite Castor Varieties & 2023 Orders
Powered by Evogene’s ELITE CASTOR VARIETIES & Yalos® | Bio-inoculant for cereal grains Subsidiary 2023 ORDERS ~$440K 18
Slide 19: Generator AI Tech Engine
GENERATOR AI TECH ENGINE Powered by Evogene’s Directing & accelerating product Subsidiary discovery & optimization Breeding programs of varieties suitable for mechanized harvest Advanced genetic Powered by screening for high Genetic yield & oil traits diversity ~200 Powered by WW germplasm Field tri
Slide 20: Seed Production Operation, Kenya, Africa
SEED PRODUCTION OPERATION, KENYA, AFRICA Oct 2024 – Key milestone in seed production operational expansion - completion of first shipment of > 100 tons of castor seeds grown and processed in Kenya. Commercial advantage: ▪ Supply in geographic proximity to customers ▪ Saving time and money on shippin
Slide 21: Potential Next Stage: Oil Production
Powered by Evogene’s POTENTIAL NEXT STAGE Subsidiary OIL PRODUCTION BIOFUEL Oil production to address growing market demands for castor oil as feedstock for biofuel and biobased industries. BIO-BASED INDUSTRIES 21
Slide 22: Agenda
AGENDA About Evogene Success Stories Value Proposition Business Strategy Summary Annex I - Financial Overview Annex II - Evogene Subsidiaries 22
Slide 23: Our Solution: Breakthrough Products
OUR SOLUTION Breakthrough Products Backed by Technology & Science PLATFORM SCIENCE Born from over a decade of intensive R&D, fueled by millions of dollars in investment, BIG DATA AI merging life-science with big- data and cutting-edge AI technology, the CPB directs and accelerates life-science produ
Slide 24: Direct and Accelerate Product Discovery & Optimization
WE DIRECT AND ACCELERATE LIFE-SCIENCE PRODUCT DISCOVERY & OPTIMIZATION Utilizing 3 dedicated AI tech-engines MICROBES The Result: Promising candidates addressing multiple development challenges towards successful SMALL life-science-based products. MOLECULES GENETIC PROBABILITY TIME COST ELEMENTS OF
Slide 25: AI Tech-Engines
AI TECH- ENGINES Discovery Direct & accelerate life-science product discovery & optimization Computational selection of the most promising candidates to initiate the product development process. Optimization Computational driven solution addressing optimization challenges for the selected candidates
Slide 26: AI Tech-Engine Dashboard
AI TECH-ENGINE DASHBOARD (Example) 26
Slide 27: Collaboration with Google Cloud
COLLABORATION with Google Cloud Oct. 31 - Collaboration with Google Cloud to pioneer generative AI foundation model for novel small molecule design. The collaboration has the power to foster breakthroughs in small molecule innovation for life science-based products. 27
Slide 28: Potential Markets for MicroBoost AI
Potential Markets for MicroBoost AI POTENTIAL (Example) MARKET DIVERSITY Microbials Therapeutic for crops microbials Food OD PHA Probiotics FO RM Structuring an & A RE ’ecosystem’ of diverse & AGRICULTU WE product types to be LLNESS Human & Dietary animal supplements probiotics developed utilizing o
Slide 29: Agenda
AGENDA About Evogene Success Stories Value Proposition Business Strategy Summary Annex I - Financial Overview Annex II - Evogene Subsidiaries 29
Slide 30: A World of Opportunities for Our AI Tech Engines
A WORLD OF OPPORTUNITIES FOR OUR AI TECH ENGINES MICROBES SMALL MOLECULES GENETIC ELEMENTS Microbials Therapeutic Crop Pharmaceuticals Improved Medical for crops microbials protection crops Cannabis Chemical Advanced Alternative Gene Food OD PHA Probiotics stimulants OD PHA wound care food OD PHA th
Slide 31: Business Strategy
BUSINESS MAXIMUM STRATEGY POTENTIAL MINIMUM Capture the value of our AI tech-engines RISK through diverse collaborative partnerships to accelerate life-science product development Partnering with experts in specific fields complements our technology, enabling groundbreaking innovations and financial
Slide 32: Business Model: Two Main Partnership Structures
BUSINESS MODEL Two Main Partnership Structures Capture the value of our AI tech-engines as product-development enablers, through: LICENSING COLLABORATION A time-limited license grant for utilizing Joint product development with a one of Evogene’s tech-engines, to a leading company utilizing related
Slide 33: Licensing Business Model
01 Business Model Licensing Potential Revenue Stream ▪ License fees & R&D reimbursements ▪ Royalties from sale of end-products ▪ Dividends to Evogene as a shareholder* ▪ Significant one-time-payment upon an exit event** Powered by *Subject to meeting the Israeli dividend tests and criteria. May no b
Slide 34: Collaboration Business Model
02 Business Model Collaboration Potential Revenue Stream ▪ Upfront payments ▪ R&D fees ▪ Milestone payments ▪ Royalties from sale of end-products Powered by 34
Slide 35: Licensing & Collaboration Current Status
LICENSING & COLLABORATION | CURRENT STATUS Licensing Collaboration MICROBES SMALL MOLECULES GENETIC ELEMENTS Therapeutic microbials Crop protection Castor for bio-based industries • Immuno-oncology program • Herbicides • Elite castor seed varieties • GI related disorders • Fungicides • Insecticides
Slide 36: Agenda
AGENDA About Evogene Success Stories Value Proposition Business Strategy Summary Annex I - Financial Overview Annex II - Evogene Subsidiaries 36
Slide 37: Vision, Mission and Business Strategy
VISION BUSINESS STRATEGY Pioneer groundbreaking life-science MAXIMUM POTENTIAL, MINIMUM RISK products rooted in microbe, small molecule, and genomics innovations. EVOGENE PARTNER AI Tech Specific Engines Expertise MISSION Novel Life-Science PRODUCT We merge scientific expertise with cutting-edge AI
Slide 38: Thank You
THANK YOU
Slide 39: Annex I Financial Overview
Annex I FINANCIAL OVERVIEW 39
Slide 40: Key Financials: Balance Sheet
KEY FINANCIALS: BALANCE SHEET Thousands of US $ 30.09.2024 31.12.2023 Key Points: Current Assets 25,359 34,469 ▪ Consolidated cash position: ~$20.0 million as of 30.09.2024 Long-Term Assets 14,755 16,632 ▪ No bank debt Total Assets 40,114 51,101 Current Liabilities (inc. ~$10m convertible SAFE at La
Slide 41: Key Financials: Income Statement
KEY FINANCIALS: BALANCE SHEET Thousands of US $ 1-9/2024 1-9/2023 Revenues 6,900 5,062 Key Points: Cost of revenues 1,928 1,294 ▪ 1-9 2024 revenues: $6.9M vs. $5.1M in 1-9 Gross profit 4,972 3,768 2023; anticipating continued growth in 2024 Research and development, net 13,247 15,232 ▪ 1-9 2024 net
Slide 42: Annex II Evogene Subsidiaries
Annex II EVOGENE SUBSIDIARIES
Slide 43: Expected Value Drivers: Ag Biologicals (Lavie Bio)
Powered by Expected Value Drivers Ag Biologicals BIO-PESTICIDES LAVIE BIO’S MISSION: Improve food quality, sustainability and LAV311 - US regulatory approval for bio-fungicide candidate for fruit rots – expected in 2025 agriculture productivity through microbiome based, AI-driven, ag-biological prod
Slide 44: Expected Value Drivers: Castor Seed Production (Casterra)
Powered by Expected Value Drivers Castor Seed Production Expanding the seed production operations in several CASTERRA’S MISSION: sites in Africa & Latin America, to fulfill all existing orders Provide an integrated industrial-scale solution for castor cultivation, utilizing our elite seed varieties,
Slide 45: Expected Value Drivers: Ag-Chemicals (AgPlenus)
Powered by Expected Value Drivers Ag-Chemicals AGPLENUS’ MISSION: HERBICIDES Design next-generation, effective, and Corteva collaboration – Drive projects towards next sustainable crop protection products by milestone leveraging predictive chemistry and biology Bayer collaboration - design additiona
Slide 46: Expected Value Drivers: Human Microbiome (Biomica)
Powered by Expected Value Drivers Human Microbiome BIOMICA’S MISSION: IMMUNO-ONCOLOGY Discovery and development of novel microbiome- Enrollment completion & Initial clinical readout of based therapeutics for human disorders, POC from first in-human study in 2024 utilizing cutting edge computational